ROCKWELL MEDICAL, INC. (RMTI) stock intrinsic value fair value estimate & owner earnings analysis

Rockwell Medical manufactures dialysate concentrates, the fluids dialysis clinics mix with water for kidney dialysis treatments, and sells almost exclusively to the small handful of large U.S. dialysis providers, including DaVita and Fresenius. It is a low-margin, high-volume manufacturing business rather than a patent-protected drug company; its former drug program (Triferic) is now a negligible part of revenue. The business changed shape in September 2023, when Rockwell bought a concentrates manufacturing operation from Evoqua, expanding its production base and customer list. Revenue grew from about $73 million in 2022 to over $101 million in 2024. But in the fall of 2024 DaVita, which had grown to roughly 45% of sales, notified Rockwell that it was moving most of its business to a competing supplier. DaVita's share of sales fell to about 16% in 2025, and revenue dropped to about $69 million. Rockwell responded by closing a South Carolina manufacturing facility in August 2025 and outsourcing part of its trucking operation, and by signing new multi-year supply agreements with other dialysis providers, university medical centers and hospital systems. Because the lost volume was lower-priced, gross margin held up much better than revenue did, and DaVita's contract has since been extended, with a price increase, through the end of 2026. Results for the first half of 2026 already show cash generation turning positive again and revenue roughly flat to slightly up versus a year earlier. We value the business from 2023 forward, treating the pre-acquisition, drug-development-era years as describing a different company. On that basis, owner earnings (cash the business throws off after real, sustaining equipment spending, and after adding back non-cash items like depreciation and stock compensation) were roughly breakeven to slightly negative in 2023, modestly positive in 2024, and roughly breakeven again in 2025 once a one-time $1 million cost from the facility closure is set aside. We treat that as the current, normalized earning power of the business, and our first-year forecast assumes only a small improvement from that level, consistent with what the first two quarters of 2026 have already shown, not a hoped-for turnaround still to come. Our base case assumes Rockwell gradually offsets the DaVita loss with new customers over the next several years, with owner earnings rising slowly to a modest, sustainable level as the leaner cost structure takes hold; we treat this as a flat, non-growing annuity beyond ten years, at a discount to a pure perpetuity, reflecting that dialysis concentrates are a competitively priced commodity where large customers retain real leverage to dual-source or threaten to make their own. On this basis we estimate the shares are worth roughly $2.10 today. Our bear case assumes the DaVita relationship ends entirely when its contract expires at the end of 2026 with no adequate replacement volume, pushing the business back into sustained cash losses for several years before it stabilizes at a bare-minimum scale; a term loan and covenant package add real financial strain in this scenario, and the business would likely need to raise additional, dilutive equity to keep operating. That case is worth only a few cents a share. Our bull case assumes Rockwell successfully replaces most of the lost volume with new higher-value contracts while keeping its leaner cost base, allowing revenue and owner earnings to recover toward, or beyond, 2024 levels; that case is worth roughly $5.10 a share. A few accounting and structural points worth flagging: we treated all of Rockwell's depreciation, stock-based compensation and other non-cash charges as add-backs to cash flow (standard treatment), then separately subtracted stock compensation and normal equipment spending as real costs, which is why our estimate of owner earnings differs from reported accounting profit. Separately, DaVita is not only Rockwell's largest customer but also holds about $15.5 million of convertible preferred stock in the company (issued in 2022, convertible into common shares at $11.00 each), which sits ahead of common shareholders in a sale or liquidation; this is a modest but real overhang we factored into how cautious we were on the downside case rather than treating as a routine balance-sheet item. Given how much of the total value in every case rests on what the business is worth ten-plus years out rather than the next decade of cash flow, and given how sharply Rockwell's fortunes can swing when a single customer relationship changes, the margin-of-safety price sits well below our base-case estimate, and a price near that estimate would require the customer-replacement story to be actually playing out in the numbers.